Pharmacokinetics of theophylline in obesity

International Journal of Clinical Pharmacology and Therapeutics

Volumn 34, Issue 9, 1996, Pages 393-395

  Zahorska Markiewicz, B ^a,b   Waluga, M ^a   Zielinski M ^a   Klin, M ^a  

^a UNIVERSITY OF SILESIA   (Poland)

^b Department of Clinical Pharmacology ^*  (Poland)

Author keywords

Obesity; Pharmacokinetics; Theophylline; Weight reducing treatment

Indexed keywords

THEOPHYLLINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE CALCULATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TRANSFORMATION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MEAN RESIDENCE TIME; OBESITY; WEIGHT REDUCTION;

ADULT; BRONCHODILATOR AGENTS; DIET; FEMALE; HUMANS; MIDDLE AGED; OBESITY; THEOPHYLLINE; WEIGHT LOSS;

EID: 0029791729     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Abernethy DR, Greenblatt DJ 1982 Pharmacokinetics of drugs in obesity. Clin Pharmacokin 7: 108-124
2. Abernethy DR, Greenblatt DJ, Divoll M, Harmatz JS, Shader RI 1981 Alterations in drug distribution and clearance due to obesity. J Pharmacol Exp Ther 217: 681-685
3. Dulloo AG 1993 Ephedrine, xanthines, and prostaglandin inhibitors: actions and interactions in the stimulation of thermogenesis. Int J Obes 17 (Suppl 1): S35-S40
4. Gal P, Jusko WJ, Yurchak AM, Franklin BA 1978 Theophylline disposition in obesity. Clin Pharmacol Ther 23: 438-444
5. Golik A, Rubio A, Weintraub M, Byrne L 1991 Elevated serum liver enzyme in obesity: a dilemma during clinical trials. Int J Obes 15: 797-801
6. Landsberg L, Young JB 1993 Sympathoadrenal activity and obesity: physiological rationale for the use of adrenergic themiogenic drugs. Int J Obes 17 (Suppl I): S29-S34
7. Mangione A, Thomas PD, Imhoff TE, Lee RV, Shum LY, Jusko WJ 1978 Pharmacokinetics of theophylline in hepatic disease. Chest 73: 616-622
8. Rizzo A, Mirabella A, Bonanno A 1988 Effect of body weight on the volume of distribution of theophylline. Lung 166: 269-276
9. Rohrbaugh TM, Danish M, Ragni MC, Yaffe SJ 1982 The effect of obesity on apparent volume of distribution of theophylline. Pediatr Pharmacol 2: 75-83
10. Shum L, Jusko WJ 1989 Effects of obesity and ancillary variables (dialysis time, drug, albumine, and fatty acid concentrations) on theophylline serum protein binding. Biopharm Drug Dispos 10: 549-562
11. Shumaker RC 1986 PKCALC: A basic interactive computer program for statistical and pharmacokinetic analysis of data. Drug Metab Rev 17: 331-348
12. Toubro S, Astrup A, Breum L, Quaade F 1993 Safety and efficacy of long-term treatment with ephedrine, caffeine, and an ephedrine/caffeine mixture. Int J Obes 17 (Suppl 1): S69-S72
13. Upton RA 1991 Pharmacokinetic interactions between theophylline and other medication. Clin Pharmacokinet 20: 66-80
14. Wójcicki J 1992 Theophylline - principles of therapeutic drug monitoring (Teofilina - zasady monitorowania stêzenia we krwi). Problemy Terapii Monitorowanej 3: 1-10
15. Zahorska-Markiewicz B 1983 Thermogenesis in obesity. J Obes Weight Regulation 2: 151-159
16. Zell M, Curtis RA, Troyer WG, Fischer JH 1985 Volume of distribution of theophylline in acute exacerbations of reversible airway disease effect of body weight. Chest 87: 212-216